|
Aug 4
|
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
|
|
Aug 4
|
Viking Therapeutics (VKTX) Is Considered a Good Investment by Brokers: Is That True?
|
|
Aug 4
|
This Biotech Stock Could Soar on Upcoming Clinical Data
|
|
Aug 3
|
2 Beaten-Down Stocks With Incredible Upside Potential
|
|
Aug 3
|
2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts
|
|
Jul 31
|
Viking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with Phase 3 VK2735 Trial
|
|
Jul 24
|
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
|
|
Jul 24
|
This Weight-Loss Stock Sank After Earnings. It’s Still a Risk for Eli Lilly, Novo Nordisk.
|
|
Jul 24
|
Viking Therapeutics Inc (VKTX) Q2 2025 Earnings Call Highlights: Navigating Increased R&D ...
|
|
Jul 23
|
Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
|
|
Jul 23
|
Viking Therapeutics, Inc. (NASDAQ:VKTX) institutional owners may be pleased with recent gains after 38% loss over the past year
|
|
Jul 22
|
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
|
|
Jul 21
|
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
|
|
Jul 20
|
These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy?
|
|
Jul 19
|
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
|
|
Jun 30
|
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
|
|
Jun 27
|
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note
|
|
Jun 26
|
Why This Weight Loss Drug Company's Stock Surged Today
|
|
Jun 26
|
Viking commences Phase III clinical programme of VK2735 for obesity
|
|
Jun 26
|
VKTX Initiates Phase 3 Study on Obesity Candidate VK2735
|